GB2364571A - Diagnosing and/or monitoring urinary tract infection - Google Patents
Diagnosing and/or monitoring urinary tract infection Download PDFInfo
- Publication number
- GB2364571A GB2364571A GB0008349A GB0008349A GB2364571A GB 2364571 A GB2364571 A GB 2364571A GB 0008349 A GB0008349 A GB 0008349A GB 0008349 A GB0008349 A GB 0008349A GB 2364571 A GB2364571 A GB 2364571A
- Authority
- GB
- United Kingdom
- Prior art keywords
- vapour
- gas
- chemicals
- urine
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019206 urinary tract infection Diseases 0.000 title claims description 44
- 238000012544 monitoring process Methods 0.000 title claims 3
- 210000002700 urine Anatomy 0.000 claims abstract description 34
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 230000004044 response Effects 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 5
- 239000002322 conducting polymer Substances 0.000 claims abstract description 5
- 229920001940 conductive polymer Polymers 0.000 claims abstract description 5
- 238000013528 artificial neural network Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 238000004401 flow injection analysis Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 235000019454 L-leucine Nutrition 0.000 claims description 2
- 239000004395 L-leucine Substances 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 239000003039 volatile agent Substances 0.000 abstract description 3
- 239000002609 medium Substances 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 241000334216 Proteus sp. Species 0.000 description 9
- 238000012549 training Methods 0.000 description 8
- 241001147693 Staphylococcus sp. Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 238000002790 cross-validation Methods 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000013473 artificial intelligence Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012855 volatile organic compound Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000002364 input neuron Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002829 antibacterial sensitivity test Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000723 chemosensory effect Effects 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 210000004205 output neuron Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/0004—Gaseous mixtures, e.g. polluted air
- G01N33/0009—General constructional details of gas analysers, e.g. portable test equipment
- G01N33/0027—General constructional details of gas analysers, e.g. portable test equipment concerning the detector
- G01N33/0031—General constructional details of gas analysers, e.g. portable test equipment concerning the detector comprising two or more sensors, e.g. a sensor array
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/497—Physical analysis of biological material of gaseous biological material, e.g. breath
- G01N33/4975—Physical analysis of biological material of gaseous biological material, e.g. breath other than oxygen, carbon dioxide or alcohol, e.g. organic vapours
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Combustion & Propulsion (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A urine sample is incubated with suitable growth medium. Volatiles produced are then extracted from the medium, eg by passing air through it, and passed to an array of sensors having different responses to the different volatile materials. The sensor outputs are analysed, preferably by neural networks and genetically, and the results are used to characterise the infection. The sensors may be conducting polymers. The growth medium may include amino acids.
Description
2364571
Introduction
Urinary tract infections (UTI) are a significant cause of morbidity with 3 million UTI cases each in the USA alone'. Thirty-one percent of nosocomial infections in medical intensive care units are attributable to UT12, and it is estimated that 20% percent of females, aged of 20 and 65 years suffer at least one episode per year. There are also links to other complicated or 3,4 chronic urological disorders such as pyelonephritis, urethritis, and prostatitis Approximately 80% of uncomplicated UTI are caused by Ecoli and 20% by enteric pathogens such as Enterococci, Klebsiellae, Proteus sp., coagulase (-) Staphylococci and 5,6 fungal opportunistic pathogens such as Candida albicans. Current diagnostic techniques require 24-48 hrs to identify pathogenic species in urine midstream specimens (: 105c ml-1) and apply antibiotic sensitivity tests. Despite the introduction of molecular tests, microscopy and culture remain the gold standard in every day clinical practice.
During the 1970s there were some early attempts to develop automated urine volatile analytical devices using advanced gas-chromatographic (GC) techniques and more than 200 volatile organic compounds (VOC) were measured 7. Additionally, others studied the stimulatory effect of certain biochemical precursors in bacterial volatile production and rapid 8 GC discrimination between Ecoli and Proteus sp., or the generation of specific urinary volatile profiles of patients with metabolic disorders, postulating the existence of certain urine biomarkers9. However lack of advanced computerised techniques to analyse specimen complexity, laborious techniques, high cost and the need for highly skilled personnel, prevented these methods from being introduced to clinical practice. Recently Phillips and co-workerslo have revealed the role of VOC as important markers in lung cancer diagnosis.
OR In this study we report the analysis of 70 specimens of human urine by the application of an intelligent diagnostic model based on novel generation, detection, and rapid recognition of urinary volatile patterns within 5 hrs of receipt of specimens in the laboratory. Methods 1" UTI recognition problem Urine samples and volatile generating kits (VGK) Twenty-five anonyinised mid steam urine samples (each approx. 20ml) were obtained from patients with a clinical diagnosis of acute uncomplicated urinary tract infection and submitted for standard microbiological analysis. From each sample, after aseptic filtering extraction of eukaryotic cells, 5ml of urine were inoculated into specially made polypropylene centrifuge bottles (50ml, Sterilin) each containing a complex medium of 60% v/v brain heart infusion (BHI) broth (Oxoid), 40% cooked meat broth (Oxoid), O.Olmg ml-1 Benzamide (Sigma), lmg ml-1 Urea, Lactose and Arabinose (Sigma), 0.05mg ml-1 Porcine/Gelatine (Oxoid), 0. 001mg ml-1 Tween 80 (Sigma), 0.75mg ml-1 of a series of amino acids (LSerine, L-Methionine, LLeucine, L-Proline, L-Valine, L-Histidine, LTryptophan, Sigma) mixed to a final volume of 20ml and incubated for 4 1/2 hrs at 37'C aerobically. Flow injection analysis (FIA) of urinary volatiles After 4 1/2 hrs of incubation to coincide with the logarithmic phase of growth, 25 VGK were placed in a 37'C water bath and directly connected with a specifically designed air-filtered sparging (bubbling) system. This consisted of Teflon tubing (Tygon), a hydrophobic biofilter (0.45Lrn PTFE, Whatman-Hepavent) and an activated carbon filter (Whatman) to provide clean air- flow above the urine headspace. A flow rate of 200ml min-1 was set automatically and environmental conditions at the sampling point were continuously monitored. The actual urine sampling time and baseline recovery per specimen was 3 min. Urine Sensorial Analysis A 14 gas-sensor array (model BH1 14-Bloodhound, Leeds, UK) employed a set of specifically tailored conducting polymers which may physically interact with urinary volatile compounds to produce a change in electrical resistance. A data capture software analysed complex volatile patterns liberated over the headspace of 25 UTI-VGK specimens and extracted multiple sensor parameters from each patient profile for ftirther artificial intelligence analysis. Intelligent UTIpattern recognition system According to a standard PHLS diagnostic protocol 20 UTI out of 25 randomly selected patient samples were identified. Nine samples were found to be infected with E. coli (e), 5 with Proteus mirabilis (p), 6 with mixed infection (ep) of Proteus sp. and Gram (+) cocci (normal flora) followed by 5 normal (n) urine samples. Microscopy and culture on selective media confirmed the diagnosis in every VGK sample. In order to improve pattern classification a set of 56 sensor parameters was extracted from 14 gas-sensor responses. Two patient sample groups were randomly selected for AI analysis: a "training set" of 16 UTIVGK (e: 6 samples, p: 3, n: 3, ep: 4, 64% of UTI patient data) and an untrained group of 9 "unknown" UTI cases (e: 3, p:2, ep:2, n:2, 36% of data). Sensor data processing employed a hybrid intelligent system of Genetic Algorithms, Back Propagation Neural Networks (GANN) and multivariate techniques such as non-parametric Principal Components Analysis (PCA), parametric Discriminant Function Analysis and cross validation (DFA-cv). Genetic supervising uses an optimisation engine, which consists of models of evolutionary combination of all input sensor parameters. A number of NN features, an addition of crossing over and a mutation rate can be used to evolve the "fittest" NN solution for a specific diagnostic problem 11,12. Evolution towards the "best" NN configuration -to learn the training set and recognise the "unknown" UTI- was processed through 10 generations. An "immigration" mode evolved a NN population pool (5NNs /generation) and replaced the "weakest" phenotypes. A setting of 2 cross-overs determined the frequency of intermingling of NN features within the same topology and a mutation rate of 0.6 created new NN phenotypes. "Genetically" selected sets of sensor parameters were also used as input variables in multivariate analysis (PCA and DFA-cv). 2 "d UTI recognition problem Urine samples and volatile generating kits (VGK) Forty-five 5ml urine samples (following eukaryotic cell filtering extraction) were collected from randomly selected patients admitted in Gloucestershire PHLS and inoculated into specially made centrifuge bottles (50ml, Sterilin) each containing 95% BHl broth (Oxoid), 5% serum bovine (Oxoid), 0.70mg ml-1 of a series of amino acids (L-Leucine, L- Alanine, LSerine, L-Valine, L-Asparagine, L-Glutamine, L-Methionine, Sigma), ling ml-1 Urea (Sigma), 0.75mgml-l Lactose (Sigma), O.Img ml-1 Casein (Oxoid), 0.3mg ml-1 Acetylcholine (Sigma) to a final volume of 20ml per VGK and incubated aerobically for 5 hrs at 37C. The urine volatile delivery and sensorial systems were the same as described previously (I st UTI problem). Intelligent UTIpattern recognition system Thirty cases of UTI were identified from 45 randomly selected samples by standard microscopy and culture: 13 patients were infected with E coli (e) , 9 with Proteus sp. (p) and 8 with coagulase (-) Staphylococcus sp., (st) . Two genetic training algorithms processed urine V data through a parallel evolutionary succession process towards competent NN solutions. The first GA analysed patient data which had been randomly divided into a "training" group of 31 urinary samples (e: 9, p: 6, st: 5 and n: 11) and a group of 14 "unknowns" (e: 4, p: 3, st: 3 and n: 4, 3 1 % of patient collected data). An evolutionary process of 5 generations (3 NNs/generation) was carried out employing I crossover and a mutation rate of 0.5. Additionally the second GA performed a much broader evolutionary optimisation analysis of 100 generations. It also attempted to analyse the same amount of patient data but with a higher ratio of "unknown" proportion (42% of collected patient data) including 26 training samples (e: 8, p:4, st:4, n:10) and 19 "unknown" UTI (e:5, p:5, st:4, n:5). A population of 600 NNs was evolved using an immigration mode, 2 crossovers and a mutation rate of 0.7 towards the "fittest" NN solution. Both "genetically" selected sensor parameters were also used to perform PCA and DFA-cv. Results I" UTI recognition problem The Genetic supervisor selected a 3-layer back-propagation NN of 35 input (normalised sensor parameters), 14 hidden and 4 output neurones. A log-sigmoid activation function was used to discriminate between 4 UTI classes. For every input urine sample a numerical target describing confidence of prediction was set as k-- I with a UTI output tolerance limit of 0.5.
A momentum of 0.35 determined the lifetime of a correction term as the training process of 16 urine VGK took place. An input noise of 0.0 16 provided a slight random variation to each UTI pattern for every training cycle. Additionally an adaptive learning rate speeded up the training procedure. The GA-NN managed to "learn" all samples after 3840 epochs and achieved a UTI prediction rate of 100%. All 9 previously untrained "unknown" UTI cases were identified correctly with a confidence of prediction ranging from 0. 81 to 1.02. Thirtyfive "genetically" selected input neurones (sensor parameters) were used to perform PCA and DFA-cv so that all UTI clusters could be displayed graphically. PCA accomplished non-parametrically a significant dimension reduction by minimising minor UTI data variations so that information could be depicted on a few two-dimensional principal component score plots. There was a complete discrimination between all UTI classes (Figure 1a). DFA identified a group of parameters that best discriminated between the 4 urine groups. Two conditions were satisfied: (a) the distance between the UTI classes was as far as possible and (b) distances within UTI clusters were as close as possible. Eventually a new axis Z was identified such that it could achieve maximum discrimination. A clear 4group separation was achieved and cross-validation reclassified correctly 7 "unknown" UTI cases (Figure 1b). Furthermore by extracting all "genetically" selected sensor parameters that had been previously used as input neurones it was possible to reveal hidden non-linear patterns characteristic of each UTI group. A combination of good sensorial sensitivity, and reproducibility was also observed (Figure 2). Figure 2: Extraction of 35 "genetically" selected sensor parameters reveals 4 different groups of non-linear patterns, (a): 9 E.coli infection, (b): 6 mixed infection, (c): 5 Proteus mirabilis infection and (d): 5 normal urine. On X-axis, (divn) stands for Divergence which describes the peak sensor maximum response. Absorption (ab.) measures the rate of resistance change during volatile absorption on the conducting polymer surface. Additionally (dsn) represents the change of resistance during desorption of volatiles and area (an) that calculates the area under the actual sensor-gram. The Y-Axis measures resistance response 2"d UTI recognition problem Two parallel evolutionary algorithms selected 2 NN solutions. The first was a 3-layer (28-124) back-propagation NN that used an adaptive learning rate, a momentum of 0.42, an input pattern noise of 0.03 and achieved a 98% prediction rate. Thirteen out of 14 "unknown" UTI samples were identified correctly with a prediction output confidence ranging from 0.75 to 1.01. The intelligent system failed to characterise only one urine sample previously diagnosed with E. coli infection. However, this single pattern confusion was limited to the case of distinguishing between E. coli infection and normal urine. Both their prediction confidence outputs were very close-0.37 for Ecoli and 0.43 for normal urine- but below a 0.5 test tolerance limit. Twenty-eight "genetically" selected parameters performed PCA and DFA, which displayed two graphical cluster separations between Proteus sp., Staphylococcus Sp. UTI and normal samples. Cross-validation reclassified correctly 6 "unknown" patient samples (Figures 3a & 4a). Figure 3. Extraction of "genetically" selected sensor parameters and two-dimensional representations of PCA clustering between: a. normal urine (n), Proteus sp. (p) and Staphylococcus sp. (st) and b: E.coli (e), Proteus sp. (p) and Staphylococcus sp. (st). (Inner and outer circles divide most closely linearly discriminated patterns from the most drifted ones, respectively). Furthermore the second 3-layer NN (22-15-4) achieved a 95% prediction rate and recognised 18 out 19 "unknown" UTI cases. Only one norinal patient sample had been mistaken for E coli infection. A two-dimensional discrimination plot between 3 of the tested UTI groups (e, st, p) was produced by PCA. DFA also separated patient samples infected with E coli, Staphylococcus sp. and non-nal urine samples. Cross validation recognised 7 "unknown" UTI cases (Figures 3b & 4b).
Figure 4. DFA and 3-group separation between: a. normal urine (n), Proteus sp. (p) and Staphylococcus sp. (st) and b. normal urine, E.coli (e) and Staphylococcus sp. Cross-validation reclassified 6 (a) and 7 (b) "unknown" UTI cases.
Discussion It has long been recognised that analysis of urine may provide valuable clinical and physiological information. In this study we have demonstrated that the application of a novel diagnostic technique combining sensor technology with artificial intelligence may lead to rapid and acurate discrimination between different infective organisms in fresh samples of urine, based on the patterns of volatile compounds produced.
In the past three decades several investigators have used gas chromatography (GQ to 13 study urine volatile compounds, postulating a potential diagnostic role in infectious and 14 metabolic diseases. Other investigators had introduced the use of biochemical nutrient precursors in volatile stimulation, such as methionine and lactose, which could trigger the production of dimethyl sulphide by Proteus sp. and ethanol by Ecoli, respectively"" within 4 bours. The deterministic nature of these studies was focused on quantitative analysis of individual volatile markers by using conventional statistical methods. However highly complex biological fluids such as urine are difficult to analyse during an active infection by conventional quantitative techniques and linear methods. It has also been shown in the past that different regions of the MHC complex can contribute to the unique individual mammalian urine volatile composition and increase its complexity 16. Lack of advanced computing methods, userfriendly techniques and detection of consistent hidden diagnostic patterns prohibited those early attempts from reaching their diagnostic goal.
We are currently investigating the hypothetical existence of 2 non-linear dynamic 17 systems, in a move towards a novel diagnostic protocol: "a" complex metabolic changes during active UTI and their expression as volatile pulses and "b" the interaction of chemosensory surfaces and urinary volatile groups and their complex pattern recognition. To understand the complexity of in vivo UTI metabolic patterns and according to our hypothesis we developed a model, which has been applied successfully in this study. Four interdependent factors appeared to be key in our model: 1. Biochemical stimulation of UTI patterns, where the use of complex media managed to drive each pathogen into different catabolic pathways within 4-5 hours and release a number of non-linear volatile patterns (to achieve this there was a direct input from Biotechnology 18-20 and specially adjusted physiological parameters of VGK such as water activity and nutrient concentration increased the stimulatory volatile effect); 2. a FIA system for rapid volatile delivery; 3. a group of sensitive conducting polymers, which sensed the UTI pulses during metabolic pathogen-VGK reactions and transformed them to non- linear patterns; and 4. a hybrid intelligent system of multiple parallel GA-NN algorithms that evolved the best diagnostic solutions and recognised "unknown" UTI cases. The above intelligent system introduces a unique biochemical "dialogue" with UTI pathogens and the disease itself de profundis. It sensed their active metabolic pulses and recognised complex profiles of such a dynamic physiological phenomenon.
Further work is currently being undertaken towards the development of a new generation of diagnostic instruments based on sensors and artificial intelligence capable of providing rapid detection of infectious agents in vitro and in vivo, with enormous implications for future clinical practice.
0
Claims (11)
1. Apparatus for use in rapidly diagnosing and / or monitoring urinary tract infection comprising:
(a) A vapour or gas generating system which by interaction with a urine sample taken from the patient results in the production of volatile chemicals that are characteristic of the infection; (b) A volatile chemical delivery system which delivers the product of the vapour or gas generating system to the detection system in a precise and reproducible way; (c) a detection system comprising an array of sensors each having a different pattern of sensitivities to potential components of the generated vapour or gas and being adapted to provide an electrical output signal in response to one or more of said components; (d) a data processing system arranged to receive said electrical output signals, said data processing system being adapted to analyse the output signals to detect patterns indicative of the presence of predetermined infections and / or stages of predetermined infections.
2. Apparatus according to claim I wherein said data processing system comprises a hybrid intelligent system that controls a search optimisation engine of genetic algorithms and a multiplicity of neural networks arranged to analyse said output signals using predetermined rules and thereby to determine said pattern.
3. Apparatus according to claim I or claim 2 wherein the detection system comprises an array of partially specific conducting polymer sensors.
4. Apparatus according to any of claim I to 3 wherein the vapour or gas delivery system comprises a flow injection system.
5. Apparatus according to any of claim I to 4 wherein the vapour or gas generating system is adapted to contain a sample of urine taken from a patient, said vapour or gas generating system including a mixture of chemicals which interact with the sample, a vessel defining a sample receiving volume and a headspace, and a means for withdrawing a gas sample from the headspace.
6. A method of rapidly diagnosing and / or monitoring urinary tract infection comprising:
(a) generating volatile chemicals that are characteristic of an infection from a urine sample taken from the patient; (b) passing said volatile chemicals to a detection system in a precise and reproducible way said detection system comprising an array of sensors each having a different pattern of sensitivities to potential components of the generated vapour or gas and being adapted to provide an electrical output signal in response to one or more of said components; (c) passing said electrical output signals to a data processing system said data processing system being adapted to analyse the output it signals to detect patterns indicative of the presence of predetermined infections and / or stages of predetermined infections.
7. A method of claim 6 which employs apparatus according to any of claim I to 5.
8. A method of claim 6 or 7 wherein the vapour or gas is generated from the sample by incubation at a controlled temperature with a mixture of chemicals.
9. A method according to claim 8 wherein the mixture of chemicals is capable of supporting significant growth of micro-organisms.
10. A method according to claim 8 or claim 9 wherein said mixture of chemicals includes one or more amino acids.
11. A method according to claim 10 wherein said amino acids comprise one or more of L-serine, L-methionine, L-leucine, L-proline, L-valine, Lhistidine and L-tryptophan.
i
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0008349A GB2364571A (en) | 2000-04-06 | 2000-04-06 | Diagnosing and/or monitoring urinary tract infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0008349A GB2364571A (en) | 2000-04-06 | 2000-04-06 | Diagnosing and/or monitoring urinary tract infection |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0008349D0 GB0008349D0 (en) | 2000-05-24 |
GB2364571A true GB2364571A (en) | 2002-01-30 |
Family
ID=9889242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0008349A Withdrawn GB2364571A (en) | 2000-04-06 | 2000-04-06 | Diagnosing and/or monitoring urinary tract infection |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2364571A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11092580B2 (en) | 2009-11-20 | 2021-08-17 | University Of The West Of England, Bristol | Diagnostic apparatus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039470A1 (en) * | 1997-03-06 | 1998-09-11 | Osmetech Plc | Detection of conditions by analysis of gases or vapours |
US5814474A (en) * | 1996-07-23 | 1998-09-29 | Becton Dickinson And Company | Direct identification of microorganisms in culture bottles |
WO2000047990A2 (en) * | 1999-02-13 | 2000-08-17 | Genzyme Virotech Gmbh | Gas analyser and the use thereof in medical diagnostics |
-
2000
- 2000-04-06 GB GB0008349A patent/GB2364571A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814474A (en) * | 1996-07-23 | 1998-09-29 | Becton Dickinson And Company | Direct identification of microorganisms in culture bottles |
WO1998039470A1 (en) * | 1997-03-06 | 1998-09-11 | Osmetech Plc | Detection of conditions by analysis of gases or vapours |
WO2000047990A2 (en) * | 1999-02-13 | 2000-08-17 | Genzyme Virotech Gmbh | Gas analyser and the use thereof in medical diagnostics |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11092580B2 (en) | 2009-11-20 | 2021-08-17 | University Of The West Of England, Bristol | Diagnostic apparatus |
Also Published As
Publication number | Publication date |
---|---|
GB0008349D0 (en) | 2000-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pavlou et al. | Use of an electronic nose system for diagnoses of urinary tract infections | |
Pavlou et al. | An intelligent rapid odour recognition model in discrimination of Helicobacter pylori and other gastroesophageal isolates in vitro | |
Gibson et al. | Detection and simultaneous identification of microorganisms from headspace samples using an electronic nose. | |
Holmberg et al. | Bacteria classification based on feature extraction from sensor data | |
US10774361B2 (en) | Microbe identification by mass spectrometry and infrared spectrometry | |
KR20150122191A (en) | Method to identify bacterial species by means of gas chromatography/mass spectrometry in biological samples | |
Namdev et al. | Sniffing out trouble: use of an electronic nose in bioprocesses | |
AU2018235992B2 (en) | Device, method, and system for identifying organisms and determining their sensitivity to toxic substances using the changes in the concentrations of metabolites present in growth medium | |
US20230250462A1 (en) | Method for the spectrometric characterization of microorganisms | |
Younts et al. | DIFFERENTIATION OF ESCHERICHIA COLI 0157: H7 FROM NON–0157: H7 E. COLI SEROTYPES USING A GAS SENSOR–BASED, COMPUTER–CONTROLLED | |
WO2000032091A2 (en) | Diagnosis of gastric and lung disorders | |
GB2364571A (en) | Diagnosing and/or monitoring urinary tract infection | |
Timmins et al. | Rapid quantitative analysis of binary mixtures of Escherichia coli strains using pyrolysis mass spectrometry with multivariate calibration and artificial neural networks | |
Huff et al. | Pyrolysis mass spectrometry of bacteria from infected human urine. I. Influence of culturing and antibiotics | |
WO2001036664A1 (en) | A method for detecting contaminating microorganisms | |
Goodfellow et al. | Curie point pyrolysis mass spectrometry and its application to bacterial systematics | |
Rondelli et al. | Volatile compounds produced by Erwinia amylovora and their potential exploitation for bacterial identification | |
Kodogiannis | Intelligent classification of bacterial clinical isolates in vitro, using an array of gas sensors | |
Kodogiannis et al. | Electronic nose: clinical diagnosis based on soft computing methodologies | |
Narayana Iyengar et al. | Identifying antibiotic-resistant strains via cell sorting and elastic-light-scatter phenotyping | |
CA2326320A1 (en) | Rapid method for detecting micro-organisms and evaluating antimicrobial activity | |
KR20240021913A (en) | Method and system for identifying optimized processing conditions for treating cells with electrical pulses. | |
Fung | Rapid methods and automation in microbiology for biomass estimation | |
Sanglier | CURIE POINT PYROLYSIS MASS SPECTROMETRY AND ITS APPLICATION TO BACTERIAL SYSTEMATICS | |
RU2113467C1 (en) | Method of bacterium identification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |